The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 9, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2023.
10-Q for Q2 FY2022, filed Aug 9, 2022
The sections below describe the company as of the FY2021 annual report.
Sells TAZVERIK, a cancer medicine, and develops other targeted cancer drugs for patients and healthcare providers.
10-K for FY2021, filed Mar 1, 2022We are a commercial-stage biopharmaceutical company that is committed to rewriting treatment for people with cancer through the discovery…View ↗
We have one approved product, TAZVERIK (tazemetostat), which was granted accelerated approval by the U.S. Food and Drug Administration, or…View ↗
TAZVERIK is available to eligible patients in the United States via a specialty distribution network. Through this specialty distribution…View ↗
Beyond tazemetostat, we are utilizing our drug discovery platform to progress preclinical efforts and discover and identify additional…View ↗
Patients’ prescriptions generate product sales through specialty pharmacies and distributors; Epizyme gets paid for TAZVERIK when those customers receive the product. Collaborators pay license fees, research costs, milestones and royalties under licensing and development agreements.
10-K for FY2021, filed Mar 1, 2022The Company sells TAZVERIK in the United States principally to a limited number of specialty pharmacies, which dispense the product…View ↗
Product revenue is recognized by the Company in an amount that reflects the consideration which the Company expects to receive in exchange…View ↗
The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture…View ↗
Exclusive Licenses – If the license to the Company’s intellectual property is determined to be distinct from the other promises or…View ↗
Research and Development Services – The promises under the Company’s collaboration and license agreements generally include research and…View ↗
Milestone Payments – At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the…View ↗
$37.4M
10-K for FY2021, filed Mar 1, 2022
$37.4M ↗
Epizyme sells TAZVERIK to specialty pharmacies, which dispense it directly to patients, and specialty distributors, which supply hospital and community practice pharmacies. It also works with pharmaceutical collaborators under licensing and research agreements.
10-K for FY2021, filed Mar 1, 2022The Company sells TAZVERIK in the United States principally to a limited number of specialty pharmacies, which dispense the product…View ↗
TAZVERIK is available to eligible patients in the United States via a specialty distribution network. Through this specialty distribution…View ↗
The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture…View ↗
No. It lost $251.1M in FY2021.
10-K for FY2021, filed Mar 1, 2022
−$238MView ↗
10-K for FY2021, filed Mar 1, 2022
−$251.1MView ↗
10-K for FY2021, filed Mar 1, 2022
−$227.3MView ↗
Grew. Revenue grew 3.7x in 4 years, from $10M in FY2017 to $37.4M in FY2021, about 39% a year.
From candidate to approved product
The older report described tazemetostat as a lead product candidate and planned applications for accelerated approval. The latest report says TAZVERIK had FDA approval for epithelioid sarcoma and follicular lymphoma and was being sold in the United States.
10-K for FY2018, filed Feb 26, 2019 10-K for FY2021, filed Mar 1, 2022We have one approved product, TAZVERIK (tazemetostat), which was granted accelerated approval by the U.S. Food and Drug Administration, or…View ↗
In January 2020, the FDA granted accelerated approval of TAZVERIK (tazemetostat), an oral, first in class, selective small molecule…View ↗
In June 2020, the FDA approved a supplemental New Drug Application, or sNDA, for TAZVERIK for adult patients with relapsed or refractory…View ↗
TAZVERIK is available to eligible patients in the United States via a specialty distribution network. Through this specialty distribution…View ↗
Broader pipeline focus
The older report included a program aimed at sickle cell disease alongside its cancer work. The latest report describes pipeline development around cancer medicines, including a candidate being tested for blood cancers.
10-K for FY2018, filed Feb 26, 2019 10-K for FY2021, filed Mar 1, 2022Beyond tazemetostat, we are utilizing our drug discovery platform to progress preclinical efforts and discover and identify additional…View ↗
Our most advanced product candidate, EZM0414, is a novel first-in-class oral inhibitor of the SETD2 HMT.View ↗
SETD2 is an HMT that plays multiple important roles in oncogenesis. Based on the potential of SETD2 inhibition demonstrated in multiple…View ↗
Competes with GSK, Johnson & Johnson, Pfizer, Daiichi Sankyo, MorphoSys, Constellation Pharmaceuticals, Novartis, Celgene, Merck &, Secura Bio, Spectrum Pharmaceuticals, Otsuka Pharmaceuticals, Foghorn Therapeutics, Forma Therapeutics, CellCentric, Kite Pharma, Gilead Sciences, and Roche
10-K for FY2021, filed Mar 1, 2022There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology…View ↗
Loading...
